Speakers coinvolti
1
Ospiti Internazionali
1
Università
1
The MAGNIFICAT Study Results Live Webinar
October 30, 2025
7 Speakers
Live streaming
From 3 PM to 4.30 PM (CET)
Main Topics
- Scientific Foundations and Study Design
- Population Profile and Dual User Behavior
- Evidence, Outcomes, and Future Perspectives
Advancing Tobacco Harm Reduction: The MAGNIFICAT Study Results
On October 30th, 2025, the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), in collaboration with ECLAT srl, will present the final results of the MAGNIFICAT project, a groundbreaking international study focused on dual users — individuals who both smoke conventional cigarettes and use non-combustion nicotine products.
The event, titled “Advancing Tobacco Harm Reduction: The MAGNIFICAT Study Results”, will be live-streamed from Catania and will feature contributions from leading researchers and international partners. The presentations will explore the scientific, behavioral, and policy implications of the data collected over the course of this large-scale, multicenter investigation.
Speakers
Riccardo Polosa
CoEHAR, University of Catania
Full Professor of Internal Medicine, pulmonologist and clinical immunologist. Founder of CoEHAR and Principal Investigator of the world's first randomized controlled trial on e-cigarette efficacy, most prolific author in e-cigarette research field.
Max Scherer
ABF GmbH, Deutschland
Medicinal chemist with expertise in analytical chemistry and data analysis. General Manager of ABF since 2015, responsible for quality system and compliance with ISO 17025, GLP, GCP standards. Active member of CORESTA Biomarker subgroups since 2013.
Arielle Selya
USA - Moderator
Behavioral scientist with expertise in quantitative methodology, epidemiology, and scientific communication. Senior Scientist at Pinney Associates and consultant to CoEHAR for e-cigarette behavioral research and critical literature review.
Jonathan Belsey
JB Medical, UK
Independent statistician and health economist specializing in new product evaluation and market access. Since 1996, runs consultancy in pharmaceuticals, diagnostics, and medical devices, focusing on clinical trial and meta-data analysis.
Nikola Pluym
ABF GmbH, Deutschland
Medicinal chemist with expertise in analytical chemistry, exposure science, and environmental epidemiology. General Manager of ABF since 2015, served as Bioanalytical Principal Investigator in numerous tobacco harm reduction clinical studies.
Simona Veigl
ABF GmbH, Deutschland
PhD student in analytical chemistry at ABF with expertise in biological specimen analysis and biomarker level determination through chromatography and mass spectrometry. Joined the company in 2023 to work primarily on the MAGNIFICAT study.
Marta Zakrzewska
ZTM Pratia, Poland
Site Manager of Warsaw clinical research unit (MTZ Clinical Research/Pratia), with expertise in managing Phase I, bioequivalence, and Phase III trials. Oversees all studies conducted under the MTZ/Pratia umbrella for the MAGNIFICAT project.
Insights
- Protocol for the “magnitude of cigarette substitution after initiation of e-cigarettes and its impact on biomarkers of exposure and potential harm in dual users” (MAGNIFICAT) study
- MAGNIFICAT project: dual user and harm reduction potential
- MAGNIFICAT Project moves forward with international workshop success
Partecipa al
No Tobacco Day 2024
Se sei interessato a partecipare alla “Conferenza Annuale CoEHAR sulla riduzione del danno” o vuoi ricevere materiale informativo sull’harm reduction in Italia e nel mondo compila il contact form. Ti risponderemo il prima possibile.